Standard BioTools LAB 深 滬
等待開盤 11-07 09:30:00 美东时间
0.636
+0.014
+2.19%
華盛通- 最 高0.6442
- 今 開0.63
- 成交量 112.26万股
- 最 低 0.6101
- 昨 收 0.6224
- 總市值 2.51亿
- 52周最高 1.72
- 市盈率 靜 --
- 換手率 0.28%
- 52周最低 0.5881
- 委 比 -57.14%
- 總股本 3.95亿
- 歷史最高 49.455
- 量 比 0.95
- 振 幅 5.48%
- 歷史最低 0.5881
- 每 手 1
- 風險率 0.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific
ARCHIMED has completed its acquisition of Standard BioTools' Microfluidics Business, renaming it Biomark Scientific. As a leader in genomic workflows, Biomark Scientific leverages proprietary microfluidics technology to offer scalable and automated solutions, including the next-generation Biomark X9 system. The company, previously part of Fluidigm, will expand its capabilities under ARCHIMED's support, focusing on genomics, clinical research, and...
11-03 12:30
Standard BioTools to sell Microfluidics business to ARCHIMED
Standard BioTools (LAB) announced Monday it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm focused exclusively on healthcare industries. The...
10-06 04:15
Standard BioTools Terminates Its Previously Announced Agreement To Sell Its Mass Cytometry Business To Multiplex Bio; Co. Enters Into A Definitive Agreement To Sell Its Mass Cytometry Business To Element Biosystems For $5.5M In Cash Payable
Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools" or the "Company") today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. ("Treeline"): Standard BioTools terminated its previously announced agreement to sell its Mass...
10-01 04:45
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
09-12 01:05
Standard BioTools Q2 Earnings Preview
Standard BioTools (LAB) is scheduled to announce Q2 earnings results on Wednesday, August 5th, after market close. The consensus EPS Estimate is -$0.03 (+66.7% Y/Y) and the consensus Revenue Estimate ...
08-05 05:35
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
Standard BioTools Inc. (NASDAQ: LAB) announced it will release its second quarter 2026 financial results on August 5, 2026, after U.S. market close. The company, committed to advancing life science tools through strategic initiatives, provides essential solutions for biomedical research. For more information, visit standardbio.com or contact investors via ir@standardbio.com.
07-22 11:00
MapLight Therapeutics Announces Changes to Board of Directors
MapLight Therapeutics announced the appointment of Martin Babler and Troy Cox to its Board of Directors, succeeding Robert Malenka and Jim Trenkle. Babler joins the Audit Committee, while Cox becomes Chair of the Nominating and Corporate Governance Committee. Both bring extensive experience in biotechnology leadership. Babler previously led Alumis Inc., Principia Biopharma Inc., and Talima Therapeutics, Inc., while Cox served as CEO of Foundation...
06-24 11:00
Why La-Z-Boy Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Shares of La-Z-Boy Inc (NYSE:LZB) rose sharply in pre-market trading after the company after the company reported better-than-expected fourth-quarter financial results and announced a $300 million share buyback. EPS for the quarter for La-Z-Boy in the fourth quarter came in at $1.26, crushing the an...
06-17 16:42
Standard BioTools To Merge With Treeline Bioscience In All-Stock Transaction That Values LAB At Estimated $460M; Combined Company Expected To Operate As Treeline Biosciences And Trade On Nasdaq Under Symbol 'TRLN'
Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools") and Treeline Biosciences, Inc. ("Treeline") today announced they have entered into a definitive merger agreement to combine in an all-stock transaction. Upon
06-08 19:34
Earnings Scheduled For May 5, 2026
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
